Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00942422 · ClinicalTrials.gov registry record · Phase 2
Green Tea Extract in Treating Patients With Monoclonal Gammopathy of Undetermined Significance and/or Smoldering Multiple Myeloma
A Phase 2 study, sponsored by Barbara Ann Karmanos Cancer Institute.
- Terminated
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT00942422 is a Phase 2 study that was terminated before completion, run by Barbara Ann Karmanos Cancer Institute. The registered enrollment target is 8 participants.
The verdict
NCT00942422, a Phase 2 study, was terminated before completion, sponsored by Barbara Ann Karmanos Cancer Institute.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
RATIONALE: Green tea extract contains ingredients that may prevent or slow the growth of monoclonal gammopathy of undetermined significance and/or smoldering multiple myeloma. PURPOSE: This phase II trial is studying how well green tea extract works in treating patients with monoclonal gammopathy of undetermined significance and/or smoldering multiple myeloma.
Interventions
- GENETIC gene expression analysis
- OTHER laboratory biomarker analysis
- GENETIC protein analysis
- DIETARY_SUPPLEMENT defined green tea catechin extract
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2009-11 |
| Est. Completion | 2012-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00942422
The ClinicalTrials.gov registry entry for NCT00942422 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Barbara Ann Karmanos Cancer Institute, which has 139 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which gene expression analysis is the first listed.
NCT00942422 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00942422 about?
NCT00942422 is a clinical study titled "Green Tea Extract in Treating Patients With Monoclonal Gammopathy of Undetermined Significance and/or Smoldering Multiple Myeloma". RATIONALE: Green tea extract contains ingredients that may prevent or slow the growth of monoclonal gammopathy of undetermined significance and/or smoldering multiple myeloma. PURPOSE: This phase II trial is studying how well green tea extract works in treating patients with monoclonal gammopathy o...
What is the current status of trial NCT00942422?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2009-11. Estimated completion is 2012-03.
What interventions are being tested in trial NCT00942422?
The interventions under investigation include: gene expression analysis (GENETIC), laboratory biomarker analysis (OTHER), protein analysis (GENETIC), defined green tea catechin extract (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00942422?
This trial is sponsored by Barbara Ann Karmanos Cancer Institute, which has 139 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.